Envestnet Asset Management Inc. lessened its stake in Astrazeneca PLC (NYSE:AZN) by 1.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 647,829 shares of the company’s stock after selling 8,510 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Astrazeneca were worth $21,948,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Wells Fargo & Company MN increased its holdings in Astrazeneca by 7.6% in the 3rd quarter. Wells Fargo & Company MN now owns 4,406,824 shares of the company’s stock worth $149,303,000 after acquiring an additional 310,389 shares in the last quarter. Wrapmanager Inc. increased its holdings in Astrazeneca by 21.1% in the 3rd quarter. Wrapmanager Inc. now owns 52,340 shares of the company’s stock worth $1,773,000 after acquiring an additional 9,120 shares in the last quarter. Intl Fcstone Inc. increased its holdings in Astrazeneca by 146.9% in the 2nd quarter. Intl Fcstone Inc. now owns 32,549 shares of the company’s stock worth $1,110,000 after acquiring an additional 19,365 shares in the last quarter. Royal Bank of Canada increased its holdings in Astrazeneca by 12.2% in the 2nd quarter. Royal Bank of Canada now owns 1,855,405 shares of the company’s stock worth $63,250,000 after acquiring an additional 201,885 shares in the last quarter. Finally, Sector Gamma AS purchased a new stake in Astrazeneca in the 3rd quarter worth $25,094,000. 14.75% of the stock is owned by institutional investors.
Astrazeneca PLC (AZN) opened at $32.17 on Tuesday. The company has a current ratio of 0.94, a quick ratio of 0.72 and a debt-to-equity ratio of 1.09. The firm has a market cap of $83,172.78, a PE ratio of 7.84, a PEG ratio of 3.19 and a beta of 0.72. Astrazeneca PLC has a 1 year low of $25.55 and a 1 year high of $35.60.
Several equities research analysts recently commented on AZN shares. BMO Capital Markets started coverage on shares of Astrazeneca in a report on Wednesday, September 6th. They issued an “outperform” rating and a $38.00 price target for the company. Sanford C. Bernstein raised shares of Astrazeneca from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $30.00 to $39.00 in a report on Friday, September 22nd. Natixis raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, September 6th. Argus reaffirmed a “buy” rating and set a $35.00 target price on shares of Astrazeneca in a research note on Friday, September 1st. Finally, Citigroup raised shares of Astrazeneca to a “buy” rating in a research note on Wednesday, October 18th. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $34.20.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
What are top analysts saying about Astrazeneca PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Astrazeneca PLC and related companies.